These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2064336)

  • 1. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
    Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
    Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
    Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
    Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
    Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E
    Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M; Tikanoja S; Brown J
    Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new tumor marker MCA in breast cancer diagnosis.
    Eskelinen M; Tikanoja S; Collan Y
    Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of CA 15-3 and MCA monoclonal antibody assays in the detection of primary and recurrent breast cancer.
    Pirolo F; Pacini P; Borsotti M; la Morgia R; Mungai R; Cappellini M; Cardona G; Cataliotti L; Marzano S; Neri B
    Anticancer Res; 1991; 11(2):729-31. PubMed ID: 2064326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated antigen CA 15-3 in the diagnostics of breast tumours.
    Eskelinen M; Tikanoja S; Valkamo E; Loikkanen M; Collan Y
    Scand J Clin Lab Invest; 1988 Nov; 48(7):653-8. PubMed ID: 3201097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCA performance in preoperative breast cancer patients.
    Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
    Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
    Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
    Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E
    Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
    Cappellari A; Bagarella M; Corradi G
    Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor markers MCA and CA-125 in the diagnosis and monitoring of breast cancer].
    Shakhtarin VV; Izotova IA; Parshkov EM; Chekin SIu; Simakova GM
    Vopr Onkol; 1992; 38(4):433-9. PubMed ID: 1300737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of mucinous-like cancer antigen (MCA) in women with breast disease: preliminary results.
    Valenti G; Zanardi S; Valtolina M; Bombardieri E; Boccardo F
    Cancer Detect Prev; 1991; 15(4):285-9. PubMed ID: 1794135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer.
    Horobin JM; Browning MC; McFarlane NP; Smith G; Preece PE; Wood RA; Cuschieri A
    J R Coll Surg Edinb; 1991 Aug; 36(4):219-21. PubMed ID: 1941734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum markers for breast cancer.
    Stenman UH; Heikkinen R
    Scand J Clin Lab Invest Suppl; 1991; 206():52-9. PubMed ID: 1947760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients.
    Stieber P; Molina R; Chan DW; Fritsche HA; Beyrau R; Bonfrer JM; Filella X; Gornet TG; Hoff T; Jäger W; van Kamp GJ; Nagel D; Peisker K; Sokoll LJ; Troalen F; Untch M; Domke I
    Clin Lab; 2003; 49(1-2):15-24. PubMed ID: 12593471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of CA 15-3 tumor marker in the diagnosis of breast cancer. A pilot study.
    Wojtacki J; Dziewulska-Bokiniec A; Skokowski J; Ciesielski D
    Neoplasma; 1994; 41(4):213-6. PubMed ID: 7935994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.